-
Mashup Score: 9Podcast: What Challenges Will Oncologists Face in 2025? - 7 day(s) ago
Dr. Nathan Pennell and Dr. John Sweetenham discuss the evolving landscape of oncology in 2025 and the challenges oncologists will be facing, including the impact of Medicare drug price negotiations, ongoing drug shortages, and the promising role of AI and telehealth in improving patient outcomes and access to clinical trials.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9Podcast: What Challenges Will Oncologists Face in 2025? - 7 day(s) ago
Dr. Nathan Pennell and Dr. John Sweetenham discuss the evolving landscape of oncology in 2025 and the challenges oncologists will be facing, including the impact of Medicare drug price negotiations, ongoing drug shortages, and the promising role of AI and telehealth in improving patient outcomes and access to clinical trials.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
RT @DrYukselUrun: What Challenges Will Oncologists Face in 2025? @ASCO @n8pennell https://t.co/UqviZEUCag https://t.co/K1AuaLOAcR
-
-
Mashup Score: 38How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer | JCO Oncology Practice - 1 month(s) ago
Until the early 2000s, advanced or metastatic non–small cell lung cancer (NSCLC) was treated as a single disease with all histologic subtypes treated alike with standard chemotherapy agents. Over the past two decades, the treatment paradigms for advanced …In this review, we discuss recent developments in the molecular profiling of non–small cell lung cancer (NSCLC), and approved and emerging targeted therapies for the treatment of NSCLC.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer | JCO Oncology Practice https://t.co/3VQDvEJ5oK #LCSM
-
-
Mashup Score: 0Expect Higher Costs for Your Health Care Benefits Next Year - 1 month(s) ago
Employers are predicting an increase of as much as 9 percent, on average, but are generally avoiding passing along much of that to their employees, industry groups say.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet-
Expect Higher Costs for Your Health Care Benefits Next Year https://t.co/V7Y1R5rzIy
-
-
Mashup Score: 09 tips for choosing a Medicare prescription drug plan - 2 month(s) ago
Medicare Part D is complex and can come with pitfalls — most significantly, plan terms and costs that may change every year.
Source: www.washingtonpost.comCategories: General Medicine News, Hem/OncsTweet-
9 tips for choosing a Medicare prescription drug plan https://t.co/YOrBgn20NX
-
-
Mashup Score: 2Nate Pennell's fundraising page for VeloSano - 4 month(s) ago
100% for the cure! Riding for my mom and all my patients living with cancer.
Source: give.velosano.orgCategories: General Medicine News, Hem/OncsTweet-
Final training rides in the bank, ready for 50 miles on Saturday for @bikeVeloSano! https://t.co/ccegrO2IUo https://t.co/nlX0cZo1Kj
-
-
Mashup Score: 2Nate Pennell's fundraising page for VeloSano - 4 month(s) ago
100% for the cure! Riding for my mom and all my patients living with cancer.
Source: give.velosano.orgCategories: General Medicine News, Hem/OncsTweet-
Final training rides in the bank, ready for 50 miles on Saturday for @bikeVeloSano! https://t.co/ccegrO2IUo https://t.co/nlX0cZo1Kj
-
-
Mashup Score: 20Outcomes for Pembrolizumab Stratified by Pemetrexed Maintenance Post Pembrolizumab–Platinum–Pemetrexed Induction in Metastatic Non-Small-Cell Lung Cancer - 4 month(s) ago
Aim: We assessed treatment patterns and outcomes in patients with metastatic nonsquamous non-small-cell lung cancer (mNSCLC) who initiated first-line pembrolizumab–platinum–pemetrexed (induction) …
Source: www.tandfonline.comCategories: General Medicine News, Hem/OncsTweet-
We recently published a slightly different analysis which suggested people continuing pemetrexed maintenance with pembro had longer PFS and OS than those who didn’t, but different data sets and definitely not conclusive. https://t.co/xeTQ9f1OGM https://t.co/gqmXwR0PkK https://t.co/ZIUAwZ7aQz
-
-
Mashup Score: 2The Hidden Splendors of Cleveland’s Museums - 4 month(s) ago
It’s not too late to enjoy some lake weather in Cleveland, where the ice cream is fabulous and there’s never any shortage of art to see — let our critic tell you where.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet-
The Hidden Splendor of Cleveland’s Museums https://t.co/ad9prVbX8g via @NYTimes
-
-
Mashup Score: 0Opinion | A $6 Billion Breakthrough or a Drop in the Bucket? - 4 month(s) ago
The government is finally negotiating drug prices.
Source: www.nytimes.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/IHPzkSqPVC via @NYTOpinion
-
RT @DrYukselUrun: What Challenges Will Oncologists Face in 2025? @ASCO @n8pennell https://t.co/UqviZEUCag https://t.co/K1AuaLOAcR